A flowcytometric analysis to efficiently quantify multiple innate immune cells and T Cell subsets in human blood

Cytometry Part A

Volumn 91, Issue 4, 2017, Pages 336-350

  Draxler, D F ^a   Madondo, M T ^a   Hanafi, G ^a   Plebanski, M ^a   Medcalf, R L ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

adaptive immunity; flow cytometry; innate immune cells; lymphoid cells; myeloid cells; T cells

Indexed keywords

BONE MARROW CELL; CRYOPRESERVATION; CYTOLOGY; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; INNATE IMMUNITY; MONONUCLEAR CELL; PROCEDURES; T LYMPHOCYTE SUBPOPULATION;

CRYOPRESERVATION; FLOW CYTOMETRY; HUMANS; IMMUNITY, INNATE; IMMUNOPHENOTYPING; LEUKOCYTES, MONONUCLEAR; MYELOID CELLS; T-LYMPHOCYTE SUBSETS;

EID: 85014445049     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.23080     Document Type: Article

References (40)

1. Paiva B, Almeida J, Perez-Andres M, Mateo G, Lopez A, Rasillo A, Vidriales MB, Lopez-Berges MC, Miguel JF, Orfao A. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry Part B, Clin Cytom 2010;78B:239–252.
2. Bocsi J, Melzer S, Dahnert I, Tarnok A. OMIP-023: 10-color, 13 antibody panel for in-depth phenotyping of human peripheral blood leukocytes. Cytometry Part A 2014;85A:781–784.
3. Gustafson MP, Lin Y, Maas ML, Van Keulen VP, Johnston PB, Peikert T, Gastineau DA, Dietz AB. A method for identification and analysis of non-overlapping myeloid immunophenotypes in humans. PloS One 2015;10:e0121546.
4. Meixlsperger S, Leung CS, Ramer PC, Pack M, Vanoaica LD, Breton G, Pascolo S, Salazar AM, Dzionek A, Schmitz J, et al. CD141+ dendritic cells produce prominent amounts of IFN-alpha after dsRNA recognition and can be targeted via DEC-205 in humanized mice. Blood 2013;121:5034–5044.
5. Benlahrech A, Duraisingham S, King D, Verhagen L, Rozis G, Amjadi P, Ford T, Kelleher P, Patterson S. Human blood CD1c dendritic cells stimulate IL-12-independent IFN-gamma responses and have a strikingly low inflammatory profile. J Leuk Biol 2015;97:873–885.
6. Franceschini D, Paroli M, Francavilla V, Videtta M, Morrone S, Labbadia G, Cerino A, Mondelli MU, Barnaba V. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Investig 2009;119:551–564.
7. La X, Zhang F, Li Y, Li J, Guo Y, Zhao H, Pang N, Ma X, Wen H, Fan H, et al. Upregulation of PD-1 on CD4(+)CD25(+) T cells is associated with immunosuppression in liver of mice infected with Echinococcus multilocularis. Int Immunopharmacol 2015;26:357–366.
8. Govindaraj C, Scalzo-Inguanti K, Madondo M, Hallo J, Flanagan K, Quinn M, Plebanski M. Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment. Clin Immunol 2013;149:97–110.
9. Govindaraj C, Madondo M, Kong YY, Tan P, Wei A, Plebanski M. Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients. Am J Hematol 2014;89:795–802.
10. Lord JM, Midwinter MJ, Chen YF, Belli A, Brohi K, Kovacs EJ, Koenderman L, Kubes P, Lilford RJ. The systemic immune response to trauma: An overview of pathophysiology and treatment. Lancet 2014;384:1455–1465.
11. Hazeldine J, Lord JM, Belli A. Traumatic brain injury and peripheral immune suppression: Primer and prospectus. Front Neurol 2015;6:235.
12. Marik PE, Flemmer M. The immune response to surgery and trauma: Implications for treatment. J Trauma Acute Care Surg 2012;73:801–808.
13. Mittag D, Proietto AI, Loudovaris T, Mannering SI, Vremec D, Shortman K, Wu L, Harrison LC. Human dendritic cell subsets from spleen and blood are similar in phenotype and function but modified by donor health status. J Immunol 2011;186:6207–6217.
14. Hellman P, Eriksson H. Early activation markers of human peripheral dendritic cells. Hum Immunol 2007;68:324–333.
15. Ou JN, Wiedeman AE, Stevens AM. TNF-alpha and TGF-beta counter-regulate PD-L1 expression on monocytes in systemic lupus erythematosus. Sci Rep 2012;2:295.
16. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, Chouaib S. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 2014;211:781–790.
17. Ebbo M, Audonnet S, Grados A, Benarous L, Mahevas M, Godeau B, Viallard JF, Piperoglou C, Cognet C, Farnarier C, et al. NK cell compartment in the peripheral blood and spleen in adult patients with primary immune thrombocytopenia. Clin Immunol (Orlando, Fla) 2015; DOI: 10.1016/j.clim.2015.11.005.
18. Peng LS, Mao FY, Zhao YL, Wang TT, Chen N, Zhang JY, Cheng P, Li WH, Lv YP, Teng YS, et al. Altered phenotypic and functional characteristics of CD3+CD56+ NKT-like cells in human gastric cancer. Oncotarget 2016; DOI: 10.18632/oncotarget.0484.
19. Guo H, Xu B, Yang X, Wang Y, Liu X, Cui C, Jiang Y. A high frequency of peripheral blood NKG2D+NK and NKT cells in euthyroid patients with new onset hashimoto's thyroiditis–a pilot study. Immunol Investig 2014;43:312–323.
20. Murdoch DM, Staats JS, Weinhold KJ. OMIP-006: Phenotypic subset analysis of human T regulatory cells via polychromatic flow cytometry. Cytometry Part A 2012;81A:281–283.
21. Read S, Greenwald R, Izcue A, Robinson N, Mandelbrot D, Francisco L, Sharpe AH, Powrie F. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol 2006;177:4376–4383.
22. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci 2003;116:217–224.
23. Comi C, Fleetwood T, Dianzani U. The role of T cell apoptosis in nervous system autoimmunity. Autoimmun Rev 2012;12:150–156.
24. Purandare AV, Somerville JE. Antagonists of CCR4 as immunomodulatory agents. Curr Top Med Chem 2006;6:1335–1344.
25. Forster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: Balancing immunity and tolerance. Nat Rev Immunol 2008;8:362–371.
26. Sanchez-Sanchez N, Riol-Blanco L, de la Rosa G, Puig-Kroger A, Garcia-Bordas J, Martin D, Longo N, Cuadrado A, Cabanas C, Corbi AL, et al. Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood 2004;104:619–625.
27. Rudiger T, Geissinger E, Muller-Hermelink HK. 'Normal counterparts' of nodal peripheral T-cell lymphoma. Hematol Oncol 2006;24:175–180.
28. Park A, Govindaraj C, Xiang SD, Halo J, Quinn M, Scalzo-Inguanti K, Plebanski M. Substantially modified ratios of effector to regulatory T cells during chemotherapy in ovarian cancer patients return to pre-treatment levels at completion: Implications for immunotherapy. Cancers (Basel) 2012;4:581–600.
29. Polz J, Remke A, Weber S, Schmidt D, Weber-Steffens D, Pietryga-Krieger A, Muller N, Ritter U, Mostbock S, Mannel DN. Myeloid suppressor cells require membrane TNFR2 expression for suppressive activity. Immun Inflamm Dis 2014;2:121–130.
30. Maney NJ, Reynolds G, Krippner-Heidenreich A, Hilkens CM. Dendritic cell maturation and survival are differentially regulated by TNFR1 and TNFR2. J Immunol 2014;193:4914–4923.
31. Hijdra D, Vorselaars AD, Grutters JC, Claessen AM, Rijkers GT. Differential expression of TNFR1 (CD120a) and TNFR2 (CD120b) on subpopulations of human monocytes. J Inflamm (London, England) 2012;9:38.
32. Li MO, Sanjabi S, Flavell RA. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 2006;25:455–471.
33. Gu L, Li H, Chen L, Ma X, Li X, Gao Y, Zhang Y, Xie Y, Zhang X. Prognostic role of lymphocyte to monocyte ratio for patients with cancer: Evidence from a systematic review and meta-analysis. Oncotarget 2016; DOI: 10.18632/oncotarget.7876.
34. Lim KP, Chun NA, Ismail SM, Abraham MT, Yusoff MN, Zain RB, Ngeow WC, Ponniah S, Cheong SC. CD4+CD25hiCD127low regulatory T cells are increased in oral squamous cell carcinoma patients. PLoS One 2014;9:e103975.
35. Chevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C, Hennart B, Allorge D, van Geel N, Van Gele M, et al. Characterization of the immune network of IDO, tryptophan metabolism, PD-L1, and in circulating immune cells in melanoma. Oncoimmunology 2015;4:e982382.
36. Govindaraj C, Tan P, Walker P, Wei A, Spencer A, Plebanski M. Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients. Clin Cancer Res 2014;20:724–735.
37. Madondo MT, Tuyaerts S, Turnbull BB, Vanderstraeten A, Kohrt H, Narasimhan B, Amant F, Quinn M, Plebanski M. Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: A study of potential oscillatory behaviour and correlations. J Transl Med 2014;12:179.
38. Mallone R, Mannering SI, Brooks-Worrell BM, Durinovic-Bello I, Cilio CM, Wong FS, Schloot NC. Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: Position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin Exp Immunol 2011;163:33–49.
39. Walker JA, Barlow JL, McKenzie AN. Innate lymphoid cells–how did we miss them?. Nat Rev Immunol 2013;13:75–87.
40. Hensley-McBain T, Heit A, De Rosa SC, McElrath MJ, Andersen-Nissen E. Optimization of a whole blood phenotyping assay for enumeration of peripheral blood leukocyte populations in multicenter clinical trials. J Immunol Methods 2014;411:23–36.